The global iron deficiency anemia therapy market size accounted for USD 5.12 billion in 2024, grew to USD 5.47 billion in 2025 and is expected to be worth around USD 9.80 billion by 2034, registering a CAGR of 6.71% between 2024 and 2034. The North America iron deficiency anemia therapy market size is calculated at USD 2.05 billion in 2024 and is estimated to grow at a CAGR of 6.84% during the forecast period.
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Iron Deficiency Anemia Therapy Market
5.1. COVID-19 Landscape: Iron Deficiency Anemia Therapy Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Iron Deficiency Anemia Therapy Market, By Therapy Type
8.1. Iron Deficiency Anemia Therapy Market, by Therapy Type, 2024-2034
8.1.1. Oral Iron Therapy
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Parenteral Iron Therapy
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Red Blood Cell Transfusion
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Others
8.1.4.1. Market Revenue and Forecast (2021-2034)
Chapter 9. Global Iron Deficiency Anemia Therapy Market, By End User
9.1. Iron Deficiency Anemia Therapy Market, by End User, 2024-2034
9.1.1. Clinics
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Hospitals
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Home Healthcare
9.1.3.1. Market Revenue and Forecast (2021-2034)
Chapter 10. Global Iron Deficiency Anemia Therapy Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
10.1.2. Market Revenue and Forecast, by End User (2021-2034)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
10.1.3.2. Market Revenue and Forecast, by End User (2021-2034)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
10.1.4.2. Market Revenue and Forecast, by End User (2021-2034)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
10.2.2. Market Revenue and Forecast, by End User (2021-2034)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
10.2.3.2. Market Revenue and Forecast, by End User (2021-2034)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
10.2.4.2. Market Revenue and Forecast, by End User (2021-2034)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
10.2.5.2. Market Revenue and Forecast, by End User (2021-2034)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
10.2.6.2. Market Revenue and Forecast, by End User (2021-2034)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
10.3.2. Market Revenue and Forecast, by End User (2021-2034)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
10.3.3.2. Market Revenue and Forecast, by End User (2021-2034)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
10.3.4.2. Market Revenue and Forecast, by End User (2021-2034)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
10.3.5.2. Market Revenue and Forecast, by End User (2021-2034)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
10.3.6.2. Market Revenue and Forecast, by End User (2021-2034)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
10.4.2. Market Revenue and Forecast, by End User (2021-2034)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
10.4.3.2. Market Revenue and Forecast, by End User (2021-2034)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
10.4.4.2. Market Revenue and Forecast, by End User (2021-2034)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
10.4.5.2. Market Revenue and Forecast, by End User (2021-2034)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
10.4.6.2. Market Revenue and Forecast, by End User (2021-2034)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
10.5.2. Market Revenue and Forecast, by End User (2021-2034)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
10.5.3.2. Market Revenue and Forecast, by End User (2021-2034)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Therapy Type (2021-2034)
10.5.4.2. Market Revenue and Forecast, by End User (2021-2034)
Chapter 11. Company Profiles
11.1. Vifor Pharma Ltd.
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Teva Pharmaceutical Industries Ltd.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Sanofi
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Pfizer Inc.
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Novartis AG
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Mylan N.V.
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Lupin
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Zydus Cadila
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. GlaxoSmithKline plc
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Fresenius SE & Co. KGaA
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample